Wealthcreatures.com
WONT BE ABLE TO PROVIDE UPDATE FOR NEXT 2 TO 3 DAYS NIFTY P/E - 34.93 STAY ALERT 📢 KEEP BOOKING PROFITS AS PER RISK IN INDIVIDUAL STOCKS TIME TO BOOK ATLEST 50% PROFITS & SIT ON CASH. KEEP RIDING TRADING BETS WITH S/L AND GO WITH TREND.RIDE THE…
NIFTY TOP - 13145
OUR 1ST RESISTANCE WAS 13140
EXACT FROM TOP U TURN FOR NIFTY
OUR 1ST RESISTANCE WAS 13140
EXACT FROM TOP U TURN FOR NIFTY
Wealthcreatures.com
LONGTERM PICK TANLA SOLUTION 6X RETURNS IN JUST 15 MONTHS 59 TO 325
TANLA SOLUTION
ALMOST 10x RETURNS IN JUST 16 MONTHS
58.50 TO 555.90
POSSIBLE # 666/777
KEEP BOOKING PROFITS AS PER RISK
ALMOST 10x RETURNS IN JUST 16 MONTHS
58.50 TO 555.90
POSSIBLE # 666/777
KEEP BOOKING PROFITS AS PER RISK
POLYCAP
CMP - 925
ACCMULATION - 900 TO 925
SUPPORT @890
TEST LEVELS - 950/990/1040++
S/L - 880 cbsl basis or as per Risk
CMP - 925
ACCMULATION - 900 TO 925
SUPPORT @890
TEST LEVELS - 950/990/1040++
S/L - 880 cbsl basis or as per Risk
Wealthcreatures.com
https://wealthcreatures.com/2020/04/16/power-mech-projects-can-it-again-powerup/ POWER MECH DEEPLY UNDERVALUED RE RATING CANDIDATE VERY 🔜🔜 VALUE BUYING CAN EMERGE
KEEP ON RADAR
ONCE CLOSED ABOVE 435 WE CAN SEE BIG UPMOVE
ONCE CLOSED ABOVE 435 WE CAN SEE BIG UPMOVE
Laurus Labs CEO Says Richcore Lifesciences’ Acquisition Will Fast-Track Biotech Ambitions
Pharmaceutical ingredients maker Laurus Labs Ltd. has found its “fourth lever of growth” in the biotech space, according to its Chief Executive Satyanarayana Chava, and its most recent acquisition will fast-track this ambition.
“The gestation period to enter the biotech space is a 6-7-year period,” he told BloombergQuint’s Menaka Doshi in an interview. “Our idea is to cut down this gestation period significantly by making an acquisition.”
Laurus Labs, on Nov. 26, closed a Rs 250-crore deal to acquire a majority stake in Richcore Lifesciences, marking its entry into the biotech space and adding to its existing three divisions - active pharmaceutical ingredients, formulations and synthesis.
The startup’s promoters and management will continue to run the business while Laurus Labs—having acquired just over 72% stake—will allow the company to scale its manufacturing.The acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. Following the successful closure of the transaction, Richcore will be renamed as Laurus Bio Pvt.
Chava expects a significant return from the investment to come from Richcore’s contract manufacturing of recombinant proteins. The startup’s first large-scale facility —with a 2,50,000 litre capacity—will be ready by March 2021.
“That’s where the quantum jump in revenues will come from.” Richcore clocked Rs 30 crore revenue in its first six months of this financial year.
Another such facility is slated to be built by the end of 2021.
View: Positive for Lauras Lab in longer run.
Pharmaceutical ingredients maker Laurus Labs Ltd. has found its “fourth lever of growth” in the biotech space, according to its Chief Executive Satyanarayana Chava, and its most recent acquisition will fast-track this ambition.
“The gestation period to enter the biotech space is a 6-7-year period,” he told BloombergQuint’s Menaka Doshi in an interview. “Our idea is to cut down this gestation period significantly by making an acquisition.”
Laurus Labs, on Nov. 26, closed a Rs 250-crore deal to acquire a majority stake in Richcore Lifesciences, marking its entry into the biotech space and adding to its existing three divisions - active pharmaceutical ingredients, formulations and synthesis.
The startup’s promoters and management will continue to run the business while Laurus Labs—having acquired just over 72% stake—will allow the company to scale its manufacturing.The acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. Following the successful closure of the transaction, Richcore will be renamed as Laurus Bio Pvt.
Chava expects a significant return from the investment to come from Richcore’s contract manufacturing of recombinant proteins. The startup’s first large-scale facility —with a 2,50,000 litre capacity—will be ready by March 2021.
“That’s where the quantum jump in revenues will come from.” Richcore clocked Rs 30 crore revenue in its first six months of this financial year.
Another such facility is slated to be built by the end of 2021.
View: Positive for Lauras Lab in longer run.
Wealthcreatures.com
IGL Accumulate 405 -409 Bigger Horizon SL 378 Short term 395 Advisable for A bit long TF T 440 / 490
IGL
10 % UPPER CIRCUIT
492
ALL TARGETS ACHIVED FOR SHORT TERM
BOOK PROFITS OR TRAIL WITH S/L 470 FOR NEXT T - 525/555++
10 % UPPER CIRCUIT
492
ALL TARGETS ACHIVED FOR SHORT TERM
BOOK PROFITS OR TRAIL WITH S/L 470 FOR NEXT T - 525/555++
Wealthcreatures.com
VENKYS EGG PRICES ON UPMOVE STOCK IS CONSOLIDATED BWT - 1400 TO 1575 CURRENTLY TRADING @ 1448 ONCE CAN AGAIN ADD ON ALL DIPS TILL 1400/1350 SLOWLY IN SIP PURELY FOR DELIVERY WITH 12 TO 18 MONTHS TIME FRAME VIEW EXPECTED TO PERFORM WELL FROM Q3 ONWARDS…
VENKYS
1700++
ONCE CLOSED ABOVE 1750 CAN SEE 2000 IN SHORT TERM
1700++
ONCE CLOSED ABOVE 1750 CAN SEE 2000 IN SHORT TERM
Wealthcreatures.com
EXPLEO Cmp - 475 - 480 Available at good discount To All Time High of 642 Expecting to reach all time high in next 3 To 6 months
EXPLEO
GOOD CONSOLIDATION HAS HAPPENED IN LAST FEW DAYS
GETTING READY FOR UPMOVE
ONCE CLOSED ABOVE 494 CAN SEE BIG MOVE IN COMING DAYS
GOOD CONSOLIDATION HAS HAPPENED IN LAST FEW DAYS
GETTING READY FOR UPMOVE
ONCE CLOSED ABOVE 494 CAN SEE BIG MOVE IN COMING DAYS
Wealthcreatures.com
DEEPAK NITRITE ONCE CLOSED ABOVE 831 NEW ALL TIME HIGH COMING 🔜🔜🔜🔜
KEEP EYES 👀
DEEPAK NITRITE
DEEPAK NITRITE
Wealthcreatures.com
KOPRAN BOUNCING BACK FROM LOWS OF 113 GETTING READY FOR NEXT LEG OF RALLY
KOPRAN
LOCKED 🔒 IN 5% UC
122
Q3 WLD BE VERY GOOD
LOCKED 🔒 IN 5% UC
122
Q3 WLD BE VERY GOOD
MASTEK GETTING READY FOR NEXT LEG 🦵 OF RALLY ONCE CLOSED ABOVE 1012
STOCK HAS MADE GOOD BASE AROUND 940 - 955
STOCK HAS MADE GOOD BASE AROUND 940 - 955